Anti-inflammatory Mechanism of Bone Marrow Mesenchymal Stem Cell Transplantation in Rat Model of Spinal Cord Injury

Cell Biochemistry and Biophysics

Volumn 71, Issue 3, 2015, Pages 1341-1347

  Han, Dongji ^a   Wu, Chenglong ^a   Xiong, Qiuju ^a   Zhou, Ling ^a   Tian, Yuke ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Bone marrow mesenchymal stem cell; Spinal cord injury; Toll like receptor 4

Indexed keywords

RATTUS;

INTERLEUKIN 1BETA; MESSENGER RNA; TUMOR NECROSIS FACTOR;

ANIMAL; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; RAT; SPINAL CORD INJURIES; SPRAGUE DAWLEY RAT;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; INFLAMMATION; INTERLEUKIN-1BETA; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SPINAL CORD INJURIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84930083883     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-014-0354-1     Document Type: Article

References (43)

1. Devivo, M. J. (2012). Epidemiology of traumatic spinal cord injury: Trends and future implications. Spinal Cord,50, 365–372.
2. Beattie, M. S., & Bresnahan, I. C. (2000). Cell death, repair, and recovery of function after spinal cord contusion injuries in rats. In R. C. Kalb & S. M. Strittmatter (Eds.), Neurobiology of spinal cord injury (pp. 1–21). Totowa, NJ: Humana Press.
3. Tator, C. H. (1995). Update on the pathophysiology and pathology of acute spinal cord injury. Brain Pathology,5, 407–413.
4. McDonald, J. W., & Sadowsky, C. (2002). Spinal-cord injury. Lancet,359, 417–425.
5. Rhoney, D. H., Luer, M. S., Hughes, M., & Hatt, J. (1996). New pharmacologic approaches to acute spinal cord injury. Pharmacotherapy.,16, 382–392.
6. Young, W. (1987). Recovery mechanisms in spinal cord injury: Implications for regenerative therapy. In F. Seil (Ed.), Frontiers of clinical Neuroscience: Neural regeneration and transplantation (pp. 156–159). New York: Alan R Liss.
7. Yip, P. K., & Malaspina, A. (2012). Spinal cord trauma and the molecular point of no return. Molecular Neurodegeneration,7, 6.
8. Anderson, D. K. (1993). Pathophysiology of spinal cord trauma. Annals of Emergency Medicine,22, 987–992.
9. Geisler, F. H., Dorsey, F. C., & Coleman, W. P. (1991). Recovery of motor function after spinal-cord injury—a randomized, placebo-controlled trial with GM-1 ganglioside. New England Journal of Medicine,324, 1829–1838.
10. Lapchak, P. A., Araujo, D. M., Song, D., et al. (2001). Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia. Stroke,32, 1220–1225.
11. Hausmann, O. N. (2003). Post-traumatic inflammation following spinal cord injury. Spinal Cord,41, 369–378.
12. Oyinbo, C. A. (2011). Secondary injury mechanisms in traumatic spinal cord injury: A nugget of this multiply cascade. Acta Neurobiologiae Experimentalis (Wars),71, 281–299.
13. Breslin, K., & Agrawal, D. (2012). The use of methylprednisolone in acute spinal cord injury: A review of the evidence, controversies, and recommendations. Pediatric Emergency Care,28, 12388.
14. Hawryluk, G. W., Rowland, J., Kwon, B. K., et al. (2008). Protection and repair of the injured spinal cord: A review of completed, ongoing, and planned clinical trials for acute spinal cord injury Neurosurg. Focus,25, E14.
15. Cadotte, D. W., & Fehlings, M. G. (2011). Spinal cord injury: A systematic review of current treatment options. Clinical Orthopaedics and Related Research,469, 7322–7327.
16. Kwon, B. K., Okon, E., Hillyer, J., et al. (2011). A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury. Journal of Neurotrauma,28, 1545.
17. Tator, C. H., Hashimoto, R., Raich, A., et al. (2012). Translational potential of preclinical trials of neuroprotection through pharmacotherapy for spinal cord injury. Journal of Neurosurgery: Spine,17, 157–229.
18. Lalu, M. M., McIntyre, L., Pugliese, C., et al. (2012). Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and meta-analysis of clinical trials. PLoS One,7, e47559.
19. Prockop, D. J., Brenner, M., Fibbe, W. E., et al. (2010). Defining the risks of mesenchymal stromal cell therapy. Cytotherapy,12, 576–578.
20. Caplan, A. I. (2009). Why are MSCs therapeutic? New data: New insight. The Journal of Pathology,217, 318–324.
21. Vawda, R., & Fehlings, M. G. (2013). Mesenchymal cells in the treatment of spinal cord injury: Current & future perspectives. Current Stem Cell Research & Therapy,8, 25–38.
22. Li, J., & Lepski, G. (2013). Cell transplantation for spinal cord injury: A systematic review. BioMed Research International,2013, 786475.
23. Fleming, J. C., Norenberg, M. D., Ramsay, D. A., et al. (2006). The cellular inflammatory response in human spinal cords after injury. Brain,129, 3249.
24. Nguyen, H. X., O’Barr, T. J., & Anderson, A. J. (2007). Polymorphonuclear leukocytes promote neurotoxicity through release of matrix metalloproteinases, reactive oxygen species, and TNF-alpha. Journal of Neurochemistry,102, 900.
25. Uccelli, A., Benvenuto, F., Laroni, A., et al. (2011). Neuroprotective features of mesenchymal stem cells. Best Practice & Research Clinical Haematology,24, 59–64.
26. Neuhuber, B., Timothy Himes, B., Shumsky, J. S., et al. (2005). Axon growth and recovery of function supported by human bone marrow stromal cells in the injured spinal cord exhibit donor variations. Brain Research,1035, 73–85.
27. Abrams, M. B., Dominguez, C., Pernold, K., et al. (2009). Multipotent mesenchymal stromal cells attenuate chronic inflammation and injury-induced sensitivity to mechanical stimuli in experimental spinal cord injury. Restorative Neurology and Neuroscience,27, 307–321.
28. Ohta, M., Suzuki, Y., Noda, T., et al. (2004). Bone marrow stromal cells infused into the cerebrospinal fluid promote functional recovery of the injured rat spinal cord with reduced cavity formation. Experimental Neurology,187, 266–278.
29. Tran, C. T., Gargiulo, C., Thao, H. D., et al. (2011). Culture and differentiation of osteoblasts on coral scaffold from human bone marrow mesenchymal stem cells. Cell and Tissue Banking,12(4), 247–261.
30. Sakata, N., Goto, M., Yoshimatsu, G., et al. (2011). Utility of co-transplanting mesenchymal stem cells in islet transplantation. World Journal of Gastroenterology,17(47), 5150–5155.
31. Allen, A. R. (1911). Surgery of experimental lesion of spinal cord equivalent to crush injury of fracture dislocation of spinal column a preliminary report. JAMA,57, 878–880.
32. David, S., & Kroner, A. (2011). Repertoire of microglial and macrophage responses after spinal cord injury. Nature Reviews Neuroscience,12(7), 388–399.
33. van den Brand, R., Heutschi, J., Barraud, Q., et al. (2012). Restoring voluntary control of locomotion after paralyzing spinal cord injury. Science,336(6085), 1182–1185.
34. Zhang, N., Yin, Y., Xu, S. J., et al. (2012). Inflammation & apoptosis in spinal cord injury. Indian Journal of Medical Research,35, 287–296.
35. David, S., & Kroner, A. (2011). Repertoire of microglial and macrophage responses after spinal cord injury. Nature Reviews Neuroscience,12, 388–399.
36. Jaerve, A., & Muller, H. W. (2012). Chemokines in CNS injury and repair. Cell and Tissue Research,349, 229–248.
37. Erşahin, M., Çevik, Ö., Akakın, D., et al. (2012). Montelukast inhibits caspase-3 activity and ameliorates oxidative damage in the spinal cord and urinary bladder of rats with spinal cord injury. Prostaglandins & Other Lipid Mediators,99(3–4), 131–139.
38. Bastien, D., & Lacroix, S. (2014). Cytokine pathways regulating glial and leukocyte function after spinal cord and peripheral nerve injury. Experimental Neurology,258, 62–77.
39. Shi, Y., Zhang, D., Huff, T. B., et al. (2011). Longitudinal in vivo coherent anti-Stokes Raman scattering imaging of demyelination and remyelination in injured spinal cord. Journal of Biomedical Optics,16(10), 106012-1–106012-4.
40. Liu, H., Peng, H., Wu, Y., et al. (2013). The promotion of bone regeneration by nanofibrous hydroxyapatite/chitosan scaffolds by effects on integrin-BMP/Smad signaling pathway in BMSCs. Biomaterials,34(18), 4404–4417.
41. Blight, A. R., & Young, W. (1989). Central axons in injured cat spinal cord recover electrophysiological function following remyelination by Schwann cells. Journal of the Neurological Sciences,91, 15–34.
42. Kayagaki, N., Wong, M. T., Stowe, I. B., et al. (2013). Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science,341(6151), 1246–1249.
43. Caicco, M. J., Zahir, T., Mothe, A. J., et al. (2013). Characterization of hyaluronan-methylcellulose hydrogels for cell delivery to the injured spinal cord. Journal of Biomedical Materials Research Part A,101A(5), 1472–1477.